Epigenetics (“Epi”; “over “ or “above” genetics) is recognized as those systems that control the expression of DNA-coded genes, but do not reside in the base pair sequences of the DNA. Rather, these control mechanisms are based on factors or molecules that bind to specific regions of the DNA (the genome), affecting gene expression. The three most important, and best understood mechanisms, are:
This report an assessment of commercial outlook for each one of these categories. It includes market size and forecast for epigenetics in pharmaceutical and diagnostic applications. Epigenetics constitutes a challenge to the long held paradigm of DNA base pair sequences as the prime determinant of the phenotype. Because of this profound intellectual shift, a vast new area of biological investigation is rapidly unfolding. This presents significant opportunities for understanding disease processes and developing the means of combating them. The examination of many diseases in a completely new light means there exist a wealth of opportunities to develop new diagnostic and therapeutic approaches. At the same time it means that outdated concepts will have to be revised. This report looks at the science behind epigenetics and deals with opportunities for product development based on epigenetic technologies and the outlook for the future in this exciting area of pharmaceutical technologies. In doing so, the report provides:
The report strives to predict the potential for epigenomics while reminding market-watchers of the challenges and possible limiting factors in this market. Mabs" and molecular tests are among the growth industries of pharmaceuticals and diagnostics, but they may have competition long-term from an unexpected source. Epigenetics is a potential game-changer in the clinical therapeutics market and significant in testing as well. It refers to technologies involving changes in genetic material that find their origins in causes other than base pairs alterations in the DNA of the host. Examples of such changes include DNA methylation and histone acetylation, both of which have been known for many years to cause changes in gene expression. This report Epigenetics, Present and Future Applications for Pharmaceuticals and Diagnostics describes the progress that has been made in our understanding of the basic science of epigenomics and considers the practical accomplishments being reported by the private sector. The study of epigenomics today finds itself at a tuningpoint, with many unanswered questions and a proliferation of opportunities forproducts based on the constant flow of new research findings. This report is essential for pharmaceutical and diagnostic marketers looking to develop future business plans and determine opportunities in a promising field.
PUBLICATION TSUNAMI SURROUNDING EPIGENETICS As I noted inmy report on Epigenetics, published by Kalorama in 2012, the field is on thecusp of an explosion, which is now taking place. According to an assessment in GeneticEngineering and Biotechnology News (http://www.genengnews.com/gen-articles/en-bloc-analysis-of-b-epigenetic-b-b-publications-b/4704/),publications are proliferating at an exponential rate, particularly in thefield of cancer research. The authors also claim that other epigenetic-baseddisease research areas are expanding rapidly, including cardiovascular,neurological and obesity targeted investigations. "In the examination of Google hits for “Epigenetics,” the phrases “exciting”, “state of the art”, “cutting edge”, “innovative”, “breakthrough” and other clichés are encountered over and over. These terms are frequently employed to cover up ideas, concepts and scientific discoveries that may NOT be cutting edge or state of the art and may be past their time, or may never have reached their time. For this reason the report will consider which of these technologies have value and may be ripe for exploitation." Related Reports: The World Market for Pain Management Drugs and DevicesMay 20, 2013 - KLI5042319 - $3,500.00 The Next Wave In Cancer Treatment - Kinase Inhibitors Dec 4, 2012 - KLI4923367 - $2,500.00 Kalorama Vaccine Market Research Report Bundle (Vaccines 2012, What's Next in Vaccines, Vaccine Production Markets) Oct 18, 2012 - KLI4891982 - $3,995.00 Early Toxicology: Markets and Approaches Sep 12, 2012 - KLI4873387 - $3,995.00 DNA Sequencing Markets (Next-Generation Systems, Capillary Systems, Consumables, Services) Sep 7, 2012 - KLI4871738 - $1,995.00 Pharmaceutical Products of the Future: 50-Company Biopharma and Traditional Pipeline Analysis to 2016 Aug 3, 2012 - KLI4859780 - $2,500.00 What's Next In Vaccines (Malaria, Diabetes, Alzheimer's, Allergies and 30 Other Targets in the 2012-2021 Vaccine Pipeline) Jun 5, 2012 - KLI3915688 - $3,995.00 Consumer Testing and The Future of DTC Genetic Testing Jun 1, 2012 - KLI3913923 - $495.00 Outsourcing in Drug Discovery: The Contract Research Organization (CRO) Market, 5th Edition May 11, 2012 - KLI3889488 - $3,995.00 World Market for Personalized Medicine Diagnostics (Biomarkers, Pharmacodiagnostics, Tumor Assays, Cardiac Risk and Other Testing) Mar 1, 2012 - KLI6640829 - $3,500.00 |
800.298.5603
Int'l: +1.240.747.3096
Questions?
Contact a research specialist >
Most Popular Research
Why Epigenomics May Be a Game-Changer in Diagnostics and Pharmaceuticals
Outsourcing in Drug Discovery: The Contract Research Organization (CRO) Market, 5th Edition
World Market for Molecular Diagnostics, 5th. Edition (Infectious Disease, Oncology, Blood Screening, Pre-Natal and Other Areas)
What's Next In Vaccines (Malaria, Diabetes, Alzheimer's, Allergies and 30 Other Targets in the 2012-2021 Vaccine Pipeline)
White Paper: Bariatric Surgery Trends
World Market for Prescription Dermatological Drugs, 8th Edition (Antiacne, Antiaging, Dermatitis, Hair Loss, Psoriasis, Skin Cancer, Melasma and Seborrhea Treatments)
|
|||||||||
Email a colleague
Printer format
Order by fax|
Privacy Policy
|
Terms and Conditions
|
Site Map
|
Return Policy
|
Press
|
Help FAQs
|